Pharma Stocks
-
CHINARES PHARMA’s Innovative Drug BGM0504 for Weight Loss Has NDA Accepted AASTOCKS Financial News
You expressly agree that the use of this app/website is at your sole risk. AASTOCKS.com Limited, HKEx Information Services Limited,…
Read More » -
Aurobindo Pharma shares fall after USFDA flags Eugia Unit III with OAI status
Shares of Aurobindo Pharma Ltd. declined on Monday, June 15, after the US Food and Drug Administration (USFDA) classified the…
Read More » -
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?
Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd. (URGN +0.75%), reported the sale of 5,222 ordinary shares for a…
Read More » -
Alnylam Taps Generative AI And Nordic Expansion As Market Lags Targets
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE. Alnylam…
Read More » -
Stocks to Watch for June 15: Vedanta, Aurobindo Pharma, JSW Energy, Dr Reddy’s and more
From Vedanta’s demerged entities market debut to JSW Energy’s wholly owned subsidiary JSW Neo Energy Ltd commissioning the full 150…
Read More » -
Ascentage Pharma (SEHK:6855) Stock After New ASCO 2026 Data A Fresh Look At Valuation
Ascentage Pharma Group International (SEHK:6855) drew fresh market attention after presenting new ASCO 2026 data on olverembatinib in chronic myeloid…
Read More » -
Astellas Pharma (TSE:4503) Stock Valuation After KRAS Trial Progress And AI Overhaul
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply…
Read More » -
Pharma, tech, EVs cheer FY27 budget as tobacco, steel count the cost
The proposed national budget for FY2026–27 has set the stage for a sweeping transformation of the country’s capital market, with…
Read More » -
NewAmsterdam Pharma (NAMS) Stock Valuation After New Obicetrapib Phase 3 And PREVAIL Trial Updates
Clinical data on obicetrapib puts NewAmsterdam Pharma in focus NewAmsterdam Pharma (NasdaqGM:NAMS) has drawn fresh attention after reporting Phase 3…
Read More » -
Teva’s Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock?
Teva Pharmaceutical Industries (TEVA +0.20%) has clawed back from the brink like few drugmakers have. After a long stretch of…
Read More »